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Synopsis 
Re-excision rates for involved margins remain high in breast-conserving surgery. Routine use of the 
cavity shave margins technique reduces positive margins and re-operations, without increasing 
costs. Cavity shaving is particularly effective in luminal cancers. 
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Abstract 
Background: Currently re-interventions for involved margins after breast-conserving surgery remain 
common. The aim of this study was to assess the capability of the cavity shave margins (CSM) 
technique to reduce positive margin rates and re-operations compared to simple lumpectomy (SL). 
The impact of CSM on the various biological portraits of breast cancer and the costs were also 
investigated. 
Methods: A retrospective review of 976 consecutive patients from a single center was performed: 
164 patients underwent SL and 812 received CSM. All patients were treated with oncoplastic 
approach. Involved margins and re-operations were compared for each group. To avoid selection 
bias, propensity score-matched analysis was performed before applying a logistic regression model. 
Main outcomes were re-analyzed for each biological portrait. Surgery and hospitalization costs for 
SL and CSM were compared. 
Results: Clear margins were found in 98.3% with CSM vs. 74.4% with SL, p<0.001. Re-operation 
rate was 18.9% with SL and 1.9% with CSM, p<0.001. After propensity score-matched logistic 
regression, OR for positive final margin status was 6.2 (95%CI 2.85-13.46, p<0.001) without CSM, 
while OR for re-intervention was 5.46 (95%CI 2.21-13.46, p<0.001). CSM significantly reduced 
positive margins and re-excisions for Luminal A, Luminal B and triple-negative breast cancers 
(p<0.001, p<0.001 and p=0.0137 respectively). SL had higher global costs compared to CSM: 
193,630.6€ vs. 177,830€ for 100 treated patients, p=0.009. 
Conclusions: CSM reduces re-excisions, mainly in luminal breast cancers, without increasing costs.  
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Introduction 
The Society of Surgical Oncology (SSO) together with the American Society for Radiation 
Oncology (ASTRO) and the American Society of Clinical Oncology (ASCO) have stated that an 
adequate margin means “no ink on tumor”.1,2 Currently, the re-operation rate for involved margins 
after lumpectomy ranges from 10% to 50%, whereas a recent consensus conference of the American 
Society of Breast Surgeons has set a reoperation rate <20% as a goal for 2020.3,4Re-interventions 
are undesirable because they lead to further sacrifice of breast tissue with inevitable aesthetic 
consequences, delay in adjuvant therapies, psychological discomfort for patients and increased re-
hospitalization costs due to additionalsurgery.5,6 Recently the cavity shave margins (CSM)technique 
has gained great interest, since it could reduce positive margins and re-interventions.7,8 However, 
routine CSM is not a standard of care in breast-conserving surgery. Moreover, the correlation 
between biological subtypes of breast cancer and involved margins in CSM has been poorly 
investigated.9 Our aim was to assess the capability of CSM to reduce positive margin rates and re-
operations compared to simple lumpectomy (SL) in a large cohort of breast cancer patients treated 
in a single center. Secondary aims were to provide a cost analysis between CSM and SL, and to 
investigate if CSM impacted differently on different biological subtypes of breast cancer. 
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Methods 
Case selection 
A retrospective review of 976 consecutive stage I-II breast cancer patients referred to the Breast 
Unit at “Luigi Sacco” University Hospital (Milan, Italy) from January 2013 to April 2016, and who 
had received breast-conserving surgery, was performed. Patients with preoperative evidence of 
lesions >5 cm or with locally advanced or multifocal disease, and patients with an unfavorable 
tumor volume/breast volume ratio underwent mastectomy. Patients who received neoadjuvant 
chemotherapy were excluded from the study. 
Surgery and perioperative procedures 
All patients underwent preoperative localization by ultrasound as previously described.10,11The 
patient was set in supine position with the upper limb abducted, and the cutaneous projection of the 
lesion was marked on the breast skin. In cases of non-palpable lesions, an ultrasound visible clip 
(MammoMark, Artemis, Hayward, CA, USA) was located in the biopsy site and the skin was 
marked. On surgery day, a skin incision was made along the mark and lumpectomy was performed. 
One hundred and sixty-four patients (16.8%) were treated by SL, while 812 (83.2%) by CSM. In 
cases of SL, the lesion was identified by the surgeon after skin incision and excised together with a 
small portion of overlying skin and underlying pectoralis fascia. In cases of CSM, after lumpectomy 
the surgeon resected a portion of breast parenchyma immediately surrounding the surgical cavity on 
each margin (Figure 1). In all patients full-thickness lumpectomy specimens were obtained with a 
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basic oncoplastic approach, remodeling breast after resection by volume replacement with minimal 
local glandular flaps to improve cosmetic outcomes. In CSM patients, breast remodeling was 
performed after margin shaving. In all cases, the surgical specimen was oriented by marking the 
cranial and medial margins with stitches. Surgery was performed by the same surgical team. 
In case of SL, the margin status was determined on all six planes of the resection and this 
represented the final margin status. In case of CSM, the margin status was assessed both on the 
lumpectomy specimen and on each cavity shaving. If one or more margins of lumpectomy were 
found to be involved but the margin status of the cavity shaving was negative, the final margins 
were considered adequate, and no further surgery was needed. Margins were considered adequate if 
no ink was found on the tumor.1,2 If the final margin status was positive, a second surgical 
procedure was proposed. In case of single margin involvement surgery consisted in re-excision of 
the breast parenchyma surrounding the surgical cavity. In case of extensive involvement (>1 
positive margins) or diagnosis of multifocality a total mastectomy was proposed. In selected 
patients with favorable features and with microscopically focal involvement of a single margin, 
adjuvant therapies and radiotherapy were proposed instead of surgery. When re-operation occurred 
in another Institute, data were retrieved from the re-operation center and included in the analysis. 
Statistical analysis 
Clinical data were collected in a prospectively-maintained database. The association between the 
use of CSM and final margin status and the re-intervention rate was assessed. Differences between 
the two study groups were assessed by chi-square or Fisher exact test for categorical variables and 
Student t test for continuous variables. Because of the non-random design of the study, we 
performed propensity score matching to reduce bias resulting from possible imbalance in observed 
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covariates between the SL and CSM groups. To generate the propensity score, a non-parsimonious 
logistic regression model was developed with CSM as the dependent variable. SL and CSM patients 
were matched in a 1:5 ratio and compared with a conditional logistic regression model adjusted 
according to post-operative variables significantly associated with outcomes, to avoid any bias.  
Subsequently main outcomes were re-analyzed for each biological portrait of breast cancer, which 
was determined on histopathological features. This allowed the different effects of CSM with 
different molecular profiles of breast cancer to be verified. Finally a cost analysis (expressed in 
euro, €) was performed for SL and CSM using data from the Hospital Cost Management Office. 
Mean surgery times for the two groups were multiplied by 6.8€ per minute of surgery, including 
staff, medications, devices and sterilization costs. Hospitalization costs were calculated by 
multiplying 634€ for each day of patient stay in the Surgery Department. Pathology costs were 
calculated from tissue processing to staining of histological sections, considering margin 
assessment on lumpectomy specimen (3 paraffin blocks per patient, 17.5€) and on each cavity 
shaving (5-6 paraffin blocks per patient, 32.5€). Staff costs were calculated considering technical 
timing of 5 minutes for each lumpectomy (3.8€) and 15 minutes for cavity shavings (11.5€). In case 
of re-intervention the costs of operations, hospitalizations and pathological analyses were added. 
Mean total costs per patient were calculated. Considering the re-intervention rate in each treatment, 
the total summed cost for 100 treated patients was calculated and compared between the two 
groups. Data analysis was carried out using STATA software (v. 13, StataCorp, Austin, USA). 
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Results 
Variables distribution between groups 
Baseline features of SL and CSM patients are reported in Table 1. Microcalcifications and 
parenchymal distortions were more frequent in SL than CSM group (23.8% vs. 11.5% and 16.5% 
vs. 5.9% respectively, p<0.001). Ductal carcinoma in situ (DCIS) was more frequent among SL 
patients (20.1% vs. 7.4%, p<0.001), while more invasive lobular cancers were found in the CSM 
group (10.1% vs. 2.4%, p<0.001). CSM patients showed increased frequency of grade I (20.4% vs. 
14.6%, p=0.002), pT1 (77% vs. 58%, p<0.001) and pN0/pNmic (76% vs. 70.1%, p=0.029) lesions 
than the SL group. 
Margin status and re-intervention rates 
Rates of involved margins on lumpectomy specimen were 25.6% for SL and 20.1% for CSM, 
p=0.116. Positive final margins decreased from 20.1% to 1.7% in CSM patients. Clear margins in 
the CSM group were found in 98.3% vs. 74.4% with SL, p<0.001. Residual cancer on cavity shave 
was detected in 20% of CSM patients, but performing CSM was sufficient to achieve adequate 
margins in 18.3% of cases. In the SL group 18.9% of patients (31/164) underwent a second surgical 
procedure to achieve adequate margins, while re-intervention was necessary in only 1.9% of CSM 
 8
patients (16/812), p<0.001 (Table 1). In SL group, 6.7% of patients (11/164) had involved margins 
but were not re-operated: 7 patients (4.3%) with favorable features had only a microscopically focal 
involvement of a single margin, therefore re-excision was avoided (supplementary Table S1); in 4 
cases (2.4%) a re-excision was proposed but patients refused re-intervention. In CSM group, 0.2% 
of patients (2/812) had a negative final margins status but were re-operated because multifocality 
was incidentally detected on cavity shave. 
Propensity score-matched analysis and multivariate logistic regression 
Lesion types and stages were differentially distributed among groups (Table 1). Since these 
parameters were preoperatively defined with a potential bias in the chosen treatment, they were 
included together with age at diagnosis in the propensity score analysis. Matching was performed 
by a 1:5 ratio between SL and CSM patients, due to the high quantitative difference in the two 
populations. The total number of subjects included in such analysis was therefore 615.After 
propensity score matching, the risk of positive final margin status was significantly higher in 
patients treated by SL, with an OR equal to 14.51 (95%CI 4.95-42.57), p<0.001. The risk of re-
intervention was also higher with SL than with CSM, with an OR of 7.73 (95%CI 2.88-20.77), 
p<0.001 (Table 2). Subsequently, the logistic regression models were implemented adding variables 
associated with poor outcome: histological type of lesion, grade and biological portrait. The 
adjusted OR for having a positive final margin status was 6.2 (95%CI 2.85-13.46, p<0.001) for SL, 
while the risk of re-intervention was 5.46 (95%CI 2.21-13.46, p<0.001) (Table 2). 
Cost analysis 
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Regarding first surgery, the mean operative time was higher with CSM than with SL (72 min vs. 
67.5 min, p=0.007). Based on operative times, first surgery costs were 459€ (±125.1€) for SL and 
489.6€ (±132.6€) for CSM (p=0.007). Total costs per single patient were 1,748.3€ (±461.1€) for SL 
and 1,759.5€ (±463.2€) for CSM (p=0.778). In case of second surgery with local re-excision, the 
total summed costs per patient were 2,738.6€ (±601.8€) for SL and 2,747.8€ (±603.8€) for CSM, 
p=0.963. If mastectomy was performed as re-intervention, the total summed costs were 2,761.3€ 
(±601.8€) and 2,770.5€ (±603.8€) respectively, p=0.986. Global costs for 100 treated patients were 
193,630.6€ (±38,562.1€) with SL vs. 177,830€ (±45,452.9€) with CSM, p=0.009 (Table 3). 
Effects of cavity shave on margin status and re-interventions according to biological portraits 
Biological portraits were equally distributed between the two groups (Table 1). A significant 
reduction in positive final margins was found upon CSM in Luminal A (from 27.3% to 1.8%, 
p<0.001), Luminal B (from 32.7% to 1.4%, p<0.001), and TNBC (from 16.7% to 0%, p=0.0137). 
Conversely, in cases of HER2-positive cancers no benefit was gained with CSM (0% vs. 4.3%, 
p=1.000). The re-intervention rates significantly decreased with CSM in Luminal A (from 16.9% to 
2.3%, p<0.001), Luminal B (from 27.3% to 1.4%, p<0.001) and TNBC (from 16.7% to 0%, 
p=0.0137), while no difference was reported for HER2-positive lesions. All these data are reported 
in Table 4. 
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Discussion  
Nowadays the rates of involved margins and re-excisions after breast-conserving surgery are still 
high.12,13 Moreover, some breast surgeons are not confident with the novel definition of clear 
margin, and often propose unnecessary re-excision in order to gain wider margins.12,14,15 CSM could 
be an interesting solution, since it resolves doubts whenever a margin is found positive on 
lumpectomy specimen. Indeed CSM avoids false positive margins arising from misleading 
interpretation of the pathologist, or from technical pitfalls related to specimen handling(e.g. ink 
infiltration into the specimen or dislocation of cancer cells near the resection margin).16,17 
We observed a rate of involved margins on lumpectomy specimens as high as 21%. This rate is 
considered relevant, since it means that about 1 every 5 patients potentially needs a re-excision.
12,13CSM significantly reduced involved margins and reinterventions. The clinical benefit from 
CSM was confirmed by the propensity score model adjusted with logistic regression: avoiding 
CSM exposed patients to 6.2-fold higher risk of positive margins, and 5.46-fold higher risk of re-
intervention. We observed lower rates of positive margins and re-interventions compared to 
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previously published data. This probably relies on several features of the suggested toolbox to 
reduce re-operations that are standards of care in our institution, such as accurate lesion localization 
by ultrasound aided by clip markers, routine cavity shave of all margins, oncoplastic approach to 
obtain full-thickness specimens, and adoption of the updated definition of a proper margin.4  
Marudanayagam has demonstrated a higher re-operation rate for SL than CSM (12.5% vs. 5.6%).
7Zavagnohasfound an even higher frequency of reoperations without CSM (21.1% vs. 5.5%).8A 
case-matched study was published by Kobbermann who demonstrated a 9-fold reduction in the risk 
of reoperation by routinely adopting CSM, but they also re-excised close margins.18Currently no 
predictor for useful CSM has been identified.19 Recently the first randomized clinical trial 
comparing CSM with SL was published, and reported a positive margin rate equal to 19% with 
CSM vs. 34% without CSM, with reduced re-operations from 21% to 10%.20Most of these studies 
were retrospective without a proper unbiased analysis, and the majority of them were prior to the 
publication of the latest guidelines on margins in breast-conserving surgery. Our study included all 
patients in which an oncoplastic approach was used, showing the benefit of CSM even in patients in 
w h i c h f u l l - t h i c k n e s s s p e c i m e n s w e r e o b t a i n e d . I n t e r e s t i n g l y , 
thisfacthasnotbeenpreviouslyinvestigated.21  
In Luminal B cancers, CSM reduced the involved margins rate from 32.7% (the highest among 
subtypes) to 1.4%, and re-operations from 27.3% to 1.4%. Conversely, CSM did not impact on 
margins or re-operations in HER2-positive breast cancers. Our data disagree with other literature, 
since HER2-positive disease is notoriously related to positive cavity shaves.9 A possible explanation 
could be that since our study population included relatively small lesions associated to grade I-II 
and N0, the HER2-lesions here-analyzed did not exhibit the same local aggressiveness of HER2 
cancers analyzed in other studies.9,22TNBC was associated with residual disease on cavity shaves in 
25.9%, and in this subgroup of patients CSM reduced positive margins and re-excisions from 16.7% 
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to 0%. In a previous study, TNBC was associated with residual invasive disease on re-excision in 
51% of cases.23,24The high rate in residual cancer and involved margins in Luminal B tumors has 
been previously observed, but its reasons are still unknown.9,25-28 Of note, the majority of our 
patients had luminal cancers, therefore no significant conclusions could be inferred for TNBC and 
HER2-positive lesions. 
A poorly explored issue is the cost-effectiveness of cavity shaving. CSM added 5 minutes to surgery 
times. Moreover, histopathology costs for each patient were higher with CSM than SL (65.3€ vs. 
21.3€). However, reduced re-excisions in CSM patients mitigated the impact of CSM on total costs. 
Similar results have been reported in another cost-analysis, where comparable costs were 
demonstrated in SL and CSM groups, despite the shorter operative times in SL than CSM (66 vs. 76 
minutes) and the higher pathological costs for CSM patients.29 
Limitations of our study could be the lack of randomization due to retrospective design and the 
approximation of biological portraits of breast cancer on pathological features instead of genetic 
profiling. However  propensity score analysis is widely accepted for surgical outcome in non-
randomized studies to reduce the selection bias. Moreover, the mentioned approximation is 
extensively used in literature.9 
 13
Conclusions 
Positive margins and re-excision rates are unacceptably high after breast-conserving surgery. 
Routine CSM associated to lumpectomy significantly reduced the need for re-excisions, especially 
in luminal cancers, even in patients treated with oncoplastic approach. A particularly low rate of re-
excision was reached by accurate localization of breast lesions as indicated in the suggested toolbox 
for successful breast-conserving surgery. A clear advantage is expected in terms of psychological 
burden for patients and promptly starting adjuvant therapies, and the total costs of the treatment do 
not appear to increase.  
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Tables 
Table 1. Distribution of baseline features among patients treated by lumpectomy only and 
lumpectomy with cavity shave margins. Margin status and re-intervention rates with and without 
performing cavity shave margins. 
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Lumpectomy 
(n = 164)
Lumpectomy + 
CSM 
(n= 812)
Total 
(n = 976) p value*
Age at diagnosis 63.4 (±10.4) 63.6 (±10.8) 63.6 (±10.7) 0.828
Lesion size (mm) 15 (±9.5) 14.6 (±7.2) 14.7 (±7.7) 0.541
Lesion type
Lump 98 (59.7%) 671 (82.6%) 769 (78.8%) <0.001
Microcalcifications 39 (23.8%) 93 (11.5%) 132 (13.5%)
Parenchymal distortion 27 (16.5%) 48 (5.9%) 75 (7.7%)
Histological type
DCIS 33 (20.1%) 60 (7.4%) 93 (9.5%) <0.001
Invasive ductal 114 (69.5%) 663 (81.6%) 777 (79.6%)
Invasive lobular 4 (2.4%) 82 (10.1%) 86 (8.8%)
Others 13 (7.9%) 7 (0.9%) 20 (2.1%)
Biological portrait**
Luminal A 77 (47.0%) 436 (53.7%) 513 (52.6%) 0.123
Luminal B 55 (33.5%) 288 (35.5%) 343 (35.1%) 0.655
HER2-positive 10 (6.1%) 23 (2.8%) 33 (3.4%) 0.054
Triple-negative 18 (11.0%) 54 (6.7%) 72 (7.4%) 0.069
N.A. 4 (2.4%) 11 (1.3%) 15 (1.5%)
Grade
I 24 (14.6%) 166 (20.4%) 190 (19.5%) 0.002
II 65 (39.6%) 370 (45.6%) 435 (44.6%)
III 49 (29.9%) 142 (17.5%) 191 (19.5%)
N.A. 26 (15.9%) 134 (16.5%) 160 (16.4%)
T stage
Tis 33 (20.1%) 60 (7.4%) 93 (9.5%) <0.001
T1 95 (58.0%) 625 (77.0%) 720 (73.8%)
T2 22 (13.4%) 110 (13.5%) 132 (13.5%)
 20
* Comparison between the two study groups: Student t test for continuous variable, Fisher exact test for categorical 
variables  
** Biological portraits were approximated as following: luminal A (positive hormone receptors and negative HER2, 
Ki67 <14%), luminal B (positive hormone receptors and negative or positive HER2, Ki67 ≥14%), HER2-positive 
(negative hormone receptors and positive HER2), and triple-negative (negative hormone receptors and negative HER2). 
T3 2 (1.2%) 3 (0.4%) 5 (0.5%)
N.A. 12 (7.3%) 14 (1.7%) 26 (2.7%)
N stage
N0/Nmic 115 (70.1%) 617 (76.0%) 732 (75%) 0.029
N1 32 (19.5%) 158 (19.4%) 190 (19.5%)
N2 12 (7.3%) 26 (3.2%) 38 (3.9%)
N3 5 (3.1%) 11 (1.4%) 16 (1.6%)
Involved margins on lumpectomy 42 (25.6%) 163 (20.1%) 205 (21.0%) 0.116
Clear margins on lumpectomy with no 
residual disease on CSM // 647 (79.8%) 647 (79.8%)
Clear margins on lumpectomy and 
residual disease on CSM (multifocality) // 2 (0.2%) 2 (0.2%)
Involved margins on lumpectomy with 
residual cancer on CSM (cleared margins) // 149 (18.3%) 149 (18.3%)
Involved margins on lumpectomy with 
residual cancer on CSM (still involved 
margins)
// 14 (1.7%) 14 (1.7%)
Final margins status 
Involved 
Clear
42 (25.6%) 
122 (74.4%)
14 (1.7%) 
798 (98.3%)
56 (5.7%) 
920 (94.3%)
<0.001
Re-intervention 
Yes 
    Local re-excision 
    Total mastectomy
31 (18.9%) 
25 (15.2%) 
6 (3.7%)
16 (1.9%) 
15 (1.8%) 
1 (0.1%)
47 (4.8%) 
40 (4.1%) 
7 (0.7%)
<0.001
No 133 (81.1%) 796 (98.1%) 929 (95.2%)
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Table 2. Results from the logistic regression analysis after propensity score matching (1:5 ratio, 615 
patients). OR and 95%CI estimating the risk of positive final margins status (A and B) and the risk 
of undergoing re-intervention (C and D). 
A) Risk of positive margins after propensity score 
matched analysis by relevant preoperative variables, 
unadjusted model 
B) Risk of positive margins, adjusted model for 
relevant post-operative variables
Coeff. 95%CI p value OR 95%CI p value
Age at diagnosis -0.002 -0.019-0.013 0.75 Histological type 1.78 1.25-2.54 0.001
Lesion type 0.78 0.54-1.02 <0.001 Grade 0.84 0.58-1.22 0.36
Stage 0.2 -0.02-0.43 0.08 Biological portrait 0.91 0.65-1.27 0.57
Positive margins 
status OR 95%CI p value
Positive margins 
status OR 95%CI p value
Lumpectomy 
without CSM 14.51 4.95-42.57 <0.001
Lumpectomy 
without CSM 6.2 2.85-13.46 <0.001
C) Risk of re-intervention after propensity score matched 
analysis by relevant preoperative variables, unadjusted 
model
D) Risk of re-intervention, adjusted model for 
relevant post-operative variables
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Coeff. 95%CI p value OR 95%CI p value
Age at diagnosis -0.002 -0.019-0.013 0.75 Histological type 1.85 1.26-2.72 0.002
Lesion type 0.78 0.54-1.02 <0.001 Grade 0.88 0.58-1.35 0.56
Stage 0.2 -0.02-0.43 0.08 Biological portrait 0.98 0.67-1.43 0.92
Re-intervention OR 95%CI p value Re-intervention OR 95%CI p value
Lumpectomy 
without CSM 7.73 2.88-20.77 <0.001
Lumpectomy  
without CSM 5.46 2.21-13.46 <0.001
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Table 3. Cost-analysis. 
*In case of re-intervention performed in another Institute, costs of the second surgery were approximated as if they were 
performed in our Breast Unit 
Simple Lumpectomy 
(n = 164)
Lumpectomy + CSM 
(n = 812) p value
Mean 
(± SD)
Costs 
(± SD)
Mean 
(± SD)
Costs 
(± SD)
Operative time (first 
surgery) - 6.8€ per min 67.5 (±18.4) 459€ (±125.1€) 72 (±19.5) 489.6€ (±132.6€) 0.007
Hospitalization stay (first 
surgery) - 634€ per day 2 (±0.7) 1,268€ (±443.8€) 1.9 (±0.7) 1,204.6€ (±443.8€) 0.095
Pathology costs (first 
surgery) 21.3€ 65.3€
Total cost per patient 
(first surgery only) 1,748.3€ (±461.1€) 1,759.5€ (±463.2€) 0.778
Operative time (second 
surgery) - 6.8€ per min* 21.3 (±10.3) 144.8€ (±70€) 21 (±10.7) 142.8€ (±72.8€) 0.936
Hospitalization stay 
(second surgery) - 634€ 
per day*
1.3 (±0.6) 824.2€ (±380.4€) 1.3 (±0.6) 824.2€ (±380.4€) 1.000
Pathology costs (second 
surgery)
21.3€ if local re-excision 
44€ if mastectomy
21.3€ if local re-excision 
44€ if mastectomy
Total cost per patient 
(first + second surgery, 
local re-excision)
2,738.6€ (±601.8€) 2,747.8€ (±603.8€) 0.963
Total cost per patient 
(first + second surgery, 
mastectomy)
2,761.3€ (±601.8€) 2,770.5€ (±603.8€) 0.986
Patients with first surgery 
only (%) 81.1% 141,787.1€  (±37,395.2€) 98.1% 172,606.9€ (±45,439.9€)
Patients re-operated with 
local re-excision (%) 15.2% 41,626.7€ (±9,147.4€) 1.8% 4,946€ (±1,086.8€)
Patients re-operated with 
mastectomy (%) 3.7% 10,216.8€ (±2,226.7€) 0.1% 277.1€ (±60.4€)
Total cost on 100 patients 193,630.6€ (±38,562.1€) 177,830€ (±45,452.9€) 0.009
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Table 4. Effects of cavity shave on margin status and re-interventions according to biological 
portrait 
Luminal A Luminal B HER2-positive TNBC p value
Margins on lumpectomy (n = 513) (n = 343) (n = 33) (n = 72)
Involved 99 (19.3%) 83 (24.2%) 3 (9.1%) 17 (23.6%) 0.105
Clear 414 (80.7%) 260 (75.8%) 30 (90.9%) 55 (76.4%)
Final margins status (patients treated by 
lumpectomy only)
(n = 77) (n = 55) (n = 10) (n = 18)
Involved 21 (27.3%) 18 (32.7%) 0 (0.0%) 3 (16.7%)
Luminal A: <0.001 
Luminal B: <0.001 
HER2-positive: 
1.000 
TNBC: 0.0137
Clear 56 (72.7%) 37 (67.3%) 10 (100.0%) 15 (83.3%)
Final margins status (patients treated by 
lumpectomy + CSM)
(n = 436) (n = 288) (n = 23) (n = 54)
Involved 8 (1.8%) 4 (1.4%) 1 (4.3%) 0 (0.0%)
Clear 428 (98.2%) 284 (98.6%) 22 (95.7%) 54 (100.0%)
Residualcancer on CSM
Yes 79 (18.1%) 65 (22.6%) 3 (13.0%) 14 (25.9%) 0.26
No 357 (81.9%) 223 (77.4%) 20 (87.0%) 40 (74.1%)
Re-intervention after lumpectomy only (n = 77) (n = 55) (n = 10) (n = 18)
Yes 13 (16.9%) 15 (27.3%) 0 (0.0%) 3 (16.7%)
Luminal A: <0.001 
Luminal B: <0.001 
HER2-positive: 
1.000 
TNBC: 0.0137
No 64 (83.1%) 40 (72.7%) 10 (100.0%) 15 (83.3%)
Re-intervention after lumpectomy + 
CSM (n = 436) (n = 288) (n = 23) (n = 54)
Yes 10 (2.3%) 4 (1.4%) 1 (4.3%) 0 (0.0%)
No 426 (97.7%) 284 (98.6%) 22 (95.7%) 54 (100.0%)
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Figure Captions 
Fig. 1 Cavity shave margins technique: all margins were separately shaved (the skin was resected 
with the lumpectomy specimen.
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